Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 5/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | PNP | P00491 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | PAH | P00439 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL625930 | 0.98 | ALDH1A1 (0.37) | KDM4EALDH1A1LMNAHPGDNOS1 | |
| Hydrochloric Acid SCHEMBL28835504 | 0.96 | KDM4E (0.33) | KDM4EALDH1A1LMNAHPGDNOS1 | |
| Hydrochloric Acid SCHEMBL16741182 | 0.75 | KDM4E (0.36) | KDM4EALDH1A1HPGDNOS1NOS3 | |
| SCHEMBL156195 | 0.70 | KDM4E (0.57) | KDM4EALDH1A1LMNAHPGDNOS1 | |
| Hydrochloric Acid SCHEMBL625929 | 0.69 | KDM4E (0.59) | KDM4EALDH1A1LMNAHPGDNOS1 | |
| SCHEMBL9054708 | 0.66 | — | — | |
| Sapropterin SCHEMBL37480 | 0.66 | NOS1 (0.65) | KDM4EALDH1A1LMNAHPGDNOS1 | |
| Sapropterin SCHEMBL258544 | 0.66 | NOS1 (0.65) | KDM4EALDH1A1LMNAHPGDNOS1 | |
| Sapropterin SCHEMBL31673726 | 0.66 | NOS1 (0.65) | KDM4EALDH1A1LMNAHPGDNOS1 | |
| Sapropterin SCHEMBL1534380 | 0.66 | NOS1 (0.65) | KDM4EALDH1A1LMNAHPGDNOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 551 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663804-B2 | Method of treating polyester textile | NOVOZYMES A/S (DK) | 2017-05-30 | — | — | US | claimed |
| US-20130183722-A1 | Compositions Comprising A Polypeptide Having Cellulolytic Enhancing Activity And A Nitrogen-Contaning Compound And Uses Thereof | NOVOZYMES, INC. (US) | 2013-07-18 | — | — | US | claimed |
| EP-2603593-A1 | COMPOSITIONS COMPRISING A POLYPEPTIDE HAVING CELLULOLYTIC ENHANCING ACTIVITY AND A NITROGEN-CONTAINING COMPOUND AND USES THEREOF | Novozymes, Inc. (US) | 2013-06-19 | — | — | EP | claimed |
| WO-2012021399-A1 | COMPOSITIONS COMPRISING A POLYPEPTIDE HAVING CELLULOLYTIC ENHANCING ACTIVITY AND A NITROGEN-CONTAINING COMPOUND AND USES THEREOF | NOVOZYMES, INC. (US) | 2012-02-16 | — | — | WO | claimed |
| US-12600996-B2 | Carbohydrate binding module variants and hybrid polypeptides comprising same | NOVOZYMES A/S (DK) | 2026-04-14 | — | — | US | disclosed |
| US-20250092434-A1 | CELLULOLYTIC ENZYME COMPOSITIONS AND USES THEREOF | NOVOZYMES, INC. (US) | 2025-03-20 | — | — | US | disclosed |
| US-12195776-B2 | Cellulolytic enzyme compositions and uses thereof | NOVOZYMES, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240376507-A9 | CELLULOLYTIC ENZYME COMPOSITIONS AND USES THEREOF | NOVOZYMES, INC. (US) | 2024-11-14 | — | — | US | disclosed |
| EP-4458964-A2 | CELLOBIOHYDROLASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME | Novozymes A/S (DK) | 2024-11-06 | — | — | EP | disclosed |
| EP-3586610-B1 | POLYPEPTIDES HAVING CELLULOLYTIC ENHANCING ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME | NOVOZYMES AS (DK) | 2024-09-25 | — | — | EP | disclosed |
| EP-3739045-B1 | CELLOBIOHYDROLASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME | NOVOZYMES AS (DK) | 2024-08-14 | — | — | EP | disclosed |
| EP-4406964-A2 | CARBOHYDRATE BINDING MODULE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME | Novozymes A/S (DK) | 2024-07-31 | — | — | EP | disclosed |
| EP-1216246-A1 | N-SUBSTITUTED 4-AMINOPTERIDINES, SYNTHESIS AND USE THEREOF AS PHARMACEUTICAL AGENT | Vasopharm Biotech GmbH & Co. KG (DE) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001021619-A1 | N-SUBSTITUTED 4-AMINOPTERIDINES, SYNTHESIS AND USE THEREOF AS PHARMACEUTICAL AGENT | VASOPHARM BIOTECH GMBH & CO. KG (DE) | 2001-03-29 | — | — | WO | disclosed |
| US-5401844-A | Chemical intermediates for treatment of parkinson*s disease | SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION (US) | 1995-03-28 | — | — | US | disclosed |
| US-5196533-A | Treatment of Parkinson*s disease, inhibitor of thymidylate synthetase | SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION, USA (US) | 1993-03-23 | — | — | US | disclosed |
| EP-0138995-B1 | REGULATION OF ENZYMES WHICH UTILIZE TETRAHYDROBIOPTERIN OR TETRAHYDROFOLATE COFACTORS WITH 6, 6-DISUBSTITUTED-TETRAHYDROPTERIDINES | South Alabama Medical Science Foundation (US) | 1991-08-14 | — | — | EP | disclosed |
| EP-0138995-A4 | REGULATION OF ENZYMES WHICH UTILIZE TETRAHYDROBIOPTERIN OR TETRAHYDROFOLATE COFACTORS WITH 6, 6-DISUBSTITUTED-TETRAHYDROPTERIDINES. | UNIV SOUTH ALABAMA (US) | 1988-05-10 | — | — | EP | disclosed |
| EP-0138995-A1 | REGULATION OF ENZYMES WHICH UTILIZE TETRAHYDROBIOPTERIN OR TETRAHYDROFOLATE COFACTORS WITH 6, 6-DISUBSTITUTED-TETRAHYDROPTERIDINES. | UNIV SOUTH ALABAMA (US) | 1985-05-02 | — | — | EP | disclosed |
| WO-1984004040-A1 | REGULATION OF ENZYMES WHICH UTILIZE TETRAHYDROBIOPTERIN OR TETRAHYDROFOLATE COFACTORS WITH 6, 6-DISUBSTITUTED-TETRAHYDROPTERIDINES | UNIV SOUTH ALABAMA (US) | 1984-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600996-B2 | Carbohydrate binding module variants and hybrid polypeptides comprising same | QPCTL, DNTT, RNGTT | KDM4E 1976/4885ALDH1A1 4658/4885LMNA 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.